PMC4690645_01
A complete response after six cycles of chemotherapy according to the contrast-enhanced chest computed tomography scan.. Notes: Contrast-enhanced chest computed tomography scan showing a mass located in the hilum of the right lung (A). This mass exhibited evident shrinkage following six cycles of chemotherapy (B).
ott-9-013Fig1.jpg
PMC4690645_01_ott-9-013Fig1.jpg
f1-ott-9-013
The patient demonstrated a partial response (PR) after four cycles and a complete response (CR) after six cycles according to the chest CT scan, which showed a streaky or coarse reticular pattern of opacities in the upper right lobe under the pleura and small nodules in the right hilum (Figure 1).
A stable disease after six additional cycles of chemotherapy according to the contrast-enhanced chest computed tomography scan.. Notes: Enhanced chest computed tomography scan on February 18, 2008, showing lung cancer with mediastinal lymph node metastasis, a right lower lobe lesion, and mediastinal lymph node enlargement (A). The lesion was significantly reduced and remained stable after six additional cycles of chemotherapy (B).
ott-9-013Fig2.jpg
PMC4690645_01_ott-9-013Fig2.jpg
f2-ott-9-013
A potential PR was assessed after cycle 8, and the patient was evaluated after cycle 10 for stable disease (SD) (Figure 2).
Enhanced brain computed tomography scan showing that erlotinib treatment combined with whole-brain radiation therapy was effective for the patient.. Notes: Enhanced brain computed tomography scan revealing metastasis in the right occipital lobe (A). This metastasis significantly shrank after erlotinib treatment combined with whole-brain radiation therapy until September 2009 (B).
ott-9-013Fig3.jpg
PMC4690645_01_ott-9-013Fig3.jpg
f3-ott-9-013
Oral erlotinib (150 mg/day) was administered from July 2008 to December 2009 (Figure 3).
Abdominal computed tomography scan showed liver and adrenal metastases, and other lesions did not change significantly.. Notes: Enhanced abdominal computed tomography scan showing liver and adrenal metastases (A, D). A brain magnetic resonance image revealed abnormal enhancement in nodules of the right occipital lobe with a history of suspected metastases and a right cerebellar lesion without abnormal enhancement (B). An enhanced chest computed tomography scan showed no significant change compared to the original film (C).
ott-9-013Fig4.jpg
PMC4690645_01_ott-9-013Fig4.jpg
f4-ott-9-013
Emission CT showed no signs of bone metastases (Figure 4).
A brain magnetic resonance image and an enhanced abdominal computed tomography showed no significant change from the previous month.. Notes: An enhanced abdominal computed tomography scan revealing multiple liver lesions and right adrenal metastases (A, C). A brain magnetic resonance image showed no significant change from the previous month (B).
ott-9-013Fig5.jpg
PMC4690645_01_ott-9-013Fig5.jpg
f5-ott-9-013
From January 23, 2010 to February 20, 2010, the patient was re-treated according to chemotherapy cycles 3 and 4 using the following medications: 140 mg of docetaxel iv on day 1 and 500 mg of carboplatin iv on day 1 (Figure 5).
Imaging findings after the patient received maintenance therapy with oral gefitinib.. Notes: A brain magnetic resonance image and an enhanced abdominal computed tomography scan shown in a stable disease (B, C). An enhanced chest computed tomography scan showed no significant change compared to the original film (A).
ott-9-013Fig6.jpg
PMC4690645_01_ott-9-013Fig6.jpg
f6-ott-9-013
Oral gefitinib treatment was initiated in June 2010 and continued until the patient died of pulmonary infection and cachexia in August 2013 (Figure 6).